文献速递脊柱关节炎

国家社会经济地位对银屑病关节炎和脊柱关节炎治疗留存与疾病活动的影响:13个欧洲国家2年证据

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.
PubMed 文献 · Ann Rheum Dis · 2026-07-13

基于欧洲脊柱关节炎研究协作网13国38911例银屑病关节炎(PsA)或中轴型脊柱关节炎(axSpA)患者2015-2021年起始b/tsDMARD的纵向数据,分析国家社会经济指标与6/12/24个月药物留存及治疗起始时疾病活动的关联。结果显示高人均GDP国家患者药物留存显著更低,且较低GDP国家治疗起始时多数疾病活动指标更差,尤其在PsA。

要点

  • 高人均GDP国家PsA/axSpA患者6/12/24个月b/tsDMARD留存显著低于中/低GDP国家。
  • 人均GDP和人类发展指数(HDI)与b/tsDMARD留存的关联最强,在axSpA女性中最突出。
  • 较低GDP国家治疗起始时多数疾病活动指标显著更差,尤其PsA。

核心结论

  • b/tsDMARD治疗留存随国家社会经济地位变化,高收入国家更早停药或换药。
  • 较低收入国家b/tsDMARD起始时疾病活动倾向更高,尤其在PsA。

研究设计与样本

  • 欧洲脊柱关节炎研究协作网收集13个欧洲国家2015-2021年起始b/tsDMARD的38911例脊柱关节炎患者纵向数据(PsA 17296例,axSpA 21615例)。
  • 采用Kaplan-Meier、混合效应Cox回归、线性回归和混合模型比较低/中/高国家社会经济指标(GDP、HDI、国民总收入、当前卫生支出、自付支出)组间差异,按疾病/b/tsDMARD线数/性别分层。

主要发现

  • 高人均GDP国家男女PsA/axSpA患者在第1/≥2线b/tsDMARD治疗6/12/24个月后药物留存显著低于中/低GDP国家(log rank P < .001)。
  • 所有社会经济指标中,更高财富与PsA和axSpA男女患者第1线b/tsDMARD更早停药相关,关联强度随指标、治疗线数和性别变化。
  • 人均GDP和HDI与b/tsDMARD留存的关联最强,在axSpA女性中最突出。
  • 国家层面,较低GDP下第1/≥2线b/tsDMARD起始时多数疾病活动指标显著更差,尤其PsA。

临床怎么用

  • 临床医生和卫生政策制定者应意识到较低收入国家b/tsDMARD停药/换药较晚且起始时疾病活动更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the association between national socioeconomic indicators, and (i) 6/12/24-month retention of biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD), and (ii) disease activity at treatment start, in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). METHODS: Longitudinal data from 13 European countries, including 38,911 patients with spondyloarthritis (17,296 PsA and 21,615 axSpA) initiating b/tsDMARDs in 2015-2021, were collected by the European Spondyloarthritis Research Collaboration Network. Kaplan-Meier, mixed-effects Cox regression, linear regression, and mixed models were used for comparisons across countries with low/medium/high national socioeconomic indicators (gross domestic product [GDP], Human Development Index [HDI], gross national income, current health expenditure, out-of-pocket expenditure), stratified by disease/b/tsDMARD number/sex. RESULTS: Drug retention was significantly lower in both men and women with PsA/axSpA from countries with high vs medium/low GDP per capita after 6/12/24 months' treatment with 1st/≥2nd b/tsDMARD (log rank P < .001). For all socioeconomic indicators, higher wealth was associated with earlier discontinuation of 1st b/tsDMARD both in PsA and axSpA men and women. The strength of associations varied across indicators, treatment lines, and sex. The strongest associations between socioeconomic measures and b/tsDMARD retention were seen with GDP per capita and HDI, and most prominently in women with axSpA. At the country level, most disease activity measures at the start of 1st/≥2nd b/tsDMARD were significantly worse with lower GDP, particularly for PsA. CONCLUSIONS: Treatment retention varies with countries' socioeconomic status. Clinicians and health policy makers should be aware of later discontinuation/switching of b/tsDMARDs and a tendency to higher country-level disease activity at b/tsDMARD initiation in lower-income countries.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Michelsen B, Polysopoulos C, Nissen MJ, et al. Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries. Ann Rheum Dis. 2026. PMID: 42443018. doi:10.1016/j.ard.2026.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。